nrf24ad 
Several members of GT1 are attending the annual congress of the Society for Neuroscience, held this week in the city of Chicago. This year is the 49th edition and has managed to gather 30,000 attendees from more than 70 countries. It is one of the most recognized and prestigious forums in the field of neuroscience … Read more SFN Congress 19-23 Oct, Chicago
On October 11, Natalia Robledinos (GT2 group) and Clara Herrera (GT3 group) defended their doctoral thesis entitled “Orchestration of the neural stem cell fate by NRF2 and TAZ” and “Melatonin- and resveratrol-based multitarget-directed agents for Alzheimer’s disease and photoswitchable muscular nicotinic receptor ligands” respectively. Thank you very much for your effort and the contributions you … Read more PhD Thesis Natalia Robledinos and Clara Herrera
After the summer holidays, we return to the Project with a consortium meeting to catch up on the latest results obtained in each work group and coordinate future activities. Thanks to the start-up of the Computational Microscopy Unit, we have been able to screen in silico more than 180 million compounds! In addition, molecular dynamics … Read more V Scientific Meeting
On July 8, Clara Herrera received the Lilly Award for early-stage researchers from the Spanish Society of Therapeutic Chemistry (SEQT) as recognition to her work entitled New neurogenic inducers with combined activities in key targets related to Alzheimer’s disease. The ceremony took place during the XIX edition of the SEQT congress, in Vitoria-Gasteiz, and was … Read more 2019 Lilly Award for Early-Stage Researchers
On June 26, the 28th edition of Farmadrid took place at La Princesa University Hospital. These annual meetings have been held since 1991, with the support of the Teófilo Hernando Foundation, with the aim of sharing the pharmacological research carried out at universities, hospitals, and pharmaceutical laboratories of the Community of Madrid. Several PhD students … Read more Farmadrid 28
Sheila Abril, member of GT1, attended the EFMC-ACSMEDI MedChem Frontiers 2019 congress held in Krakow (Poland), on June 10-13. The American Chemical Society and the European Federation of Medical Chemistry organize this bi-annual event that brings together 300 participants from the Drug R&D academic and industrial sectors (medical chemists, bioinformatics, biologists, pharmacologists, toxicologists, etc.). Sheila … Read more EFMC-ACSMEDI MedChem Frontiers 2019 Congress
A team of researchers from different universities and research centers form the United States, Japan, Australia, Sweden, United Kingdom and Austria led by Dr. Peter T. Nelson has identified a new dementia traditionally diagnosed as Alzheimer’s Disease (AD). This new proteinopathy has been called LATE (limbic-predominant age-related TDP-43 encephalopathy), and about a quarter of people … Read more New type of dementia identified
Yesterday we celebrated the IV Scientific Meeting of the project. Eric del Sastre, Felipe Franco, Raquel Fernández and Santiago Stabile presented the latest results of each working group. Thank all of you for your communications and contributions, it is clear how enriching it is to bring together people from different disciplines for having good ideas … Read more IV Scientific Meeting
The group from the Institute of Medical Chemistry (GT3) attended last march the 63rd edition of the Annual Congress of the Biophysical Society, held in Baltimore (USA). GT3 presented the results obtained in collaboration with Dr. Carlos A. Villalba-Galea (University of the Pacific, California, USA) related to the development of muscular nicotinic acetylcholine receptors (nAChR) … Read more GT3 attended the 63rd edition of the Biophysical Society Annual Congress
On April 5, 2019 Patrycja Michalska Dziama, member of the NRF24AD project (GT1), defended her doctoral thesis entitled “Novel Nrf2 inducers with multitarget activities for the treatment of neurodegenerative diseases”, under the supervision of Dr. Rafael Léon and Dr. Manuela G. López. Patrycja’s thesis project proposes the synthesis of compounds directed to multiple targets with … Read more Patrycja Michalska’s doctoral thesis
NRF24AD is a project co-funded by the Community of Madrid and the European Union Structural Funds, through the call “R&D Activities Programs among Biomedicine research groups from the Community of Madrid”.
Project Reference: S2017/BMD3827
Start date: 01/01/2018
End date: 31/12/2021
